REGENXBIO Inc. - 10-Q Filing
REGENXBIO Inc. reports Q3 2026 financial results including royalty revenue from GlaxoSmithKline and Nippon Shinyaku collaborations.
Tickers: $RGNX
REGENXBIO Inc. reports Q3 2026 financial results including royalty revenue from GlaxoSmithKline and Nippon Shinyaku collaborations.
Tickers: $RGNX